Retrospective Collection of Effectiveness and Safety Data From Patients Treated With Liraglutide or DPP-4 Inhibitor in Primary Care in Europe

Novo Nordisk A/S952 enrolled

Overview

This study is conducted in Europe. The aim of this study is to demonstrate the clinical effectiveness and safety of liraglutide and dipeptidyl peptidase-4 (DPP-4) inhibitor therapy in routine primary care in Europe.

Study Type

OBSERVATIONAL

Enrollment

952

Conditions

Diabetes Diabetes Mellitus, Type 2

Interventions

liraglutideDRUG

Anonymised patient level data will be collected by the patients' own general practitioner and electronic case report form (eCRF) will be used to capture the data.

Eligibility

Sex: ALL

Medical Language ↔ Plain English

Inclusion Criteria: * Patients treated with liraglutide or DPP-4 inhibitors, according to license in respective participating country with data available for 12 (+/- 2) months Exclusion Criteria: * Patients treated with liraglutide or DPP-4 inhibitors, outside of license in respective participating country

Locations (4)

Unnamed facility

Paris La Défense Cedex, France

Unnamed facility

Mainz, Germany

Unnamed facility

Madrid, Spain

Unnamed facility

Crawley, United Kingdom

Outcomes

Primary Outcomes

Change in HbA1c (glycosylated haemoglobin)

Time frame: Baseline (anytime within 3 months before therapy initiation), month 12 (+/-2)

Secondary Outcomes

Change in body weight

Time frame: Baseline (anytime within 3 months before therapy initiation), month 12 (+/-2)

Change in systolic blood pressure

Time frame: Baseline (anytime within 3 months before therapy initiation), month 12 (+/-2)

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.